We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Mar 2022 - 09 Mar 2022
Virtual Venue

Commercial RT-PCR Tests Compared to Culture for Bacterial Gastroenteritis

By LabMedica International staff writers
Posted on 11 Jan 2022
Print article
Image: ProGastro SSCS is a multiplex real time PCR for the detection and differentiation of Salmonella, Shigella, Campylobacter, (C. jejuni and C. coli only, undifferentiated) nucleic acids and Shiga Toxin 1 (stx1) and Shiga Toxin 2 (stx2) genes (Photo courtesy of Hologic)
Image: ProGastro SSCS is a multiplex real time PCR for the detection and differentiation of Salmonella, Shigella, Campylobacter, (C. jejuni and C. coli only, undifferentiated) nucleic acids and Shiga Toxin 1 (stx1) and Shiga Toxin 2 (stx2) genes (Photo courtesy of Hologic)
Nucleic acid-based testing (culture-independent diagnostic testing, CIDT) for bacterial gastroenteritis offers three major advantages over culture-based diagnosis: it has better analytical sensitivity, is less labor intensive through automation, and has faster turnaround times.

Multiple commercial nucleic acid test assays (i.e. real-time PCR, RT-PCR) are available, testing at a minimum of four pathogens (Salmonella, Campylobacter, Shiga toxin-producing Escherichia coli (STEC), and Shigella). However, there are many caveats associated with CIDT for bacterial gastroenteritis, and gaps in the evaluation of commercial assays.

Clinical Microbiologists at the University of Calgary (Calgary, AB, Canada) and their colleagues used clinical stool specimens and contrived samples comprising commonly circulating species, serotypes, biovars, and/or toxin subtypes were for a comparison of four commercial RT-PCR tests. The four tests were: RIDAGENE Bacterial Stool Panel and EHEC/EPEC Panel (R-Biopharm AG, Darmstadt, Germany); FTD Bacterial Gastroenteritis assay (Fast Track Diagnostics, Luxembourg); BD MAX Enteric Bacterial Panel and Extended Enteric Bacterial Panel (BD Canada, Mississauga, ON, Canada); Prodesse ProGastr SSCS Assay (Hologic Inc., San Diego, CA, USA).

The four commercial RT-PCR assays were challenged with 67 contrived stool specimens, each spiked with an isolate representing different Campylobacter species, Salmonella serotypes, Shigella species and serotypes, STEC toxin subtypes, Y. enterocolitica serotypes/biotypes, and Yersina spp; these isolates are the common circulating types in Alberta, Canada. All assays gave positive results for C. jejuni, C. coli, Y. enterocolitica, and all species and serotypes of Shigella, but negative results for Y. non-enterocoltica spp. and C. upsaliensis. Most Shiga toxin subtypes were detected by all assays except for stx2f, which was detected by Ridagene.

The performance of the four commercial assays was assessed using 171 clinical fecal specimens collected prospectively, which were initially tested by culture at the frontline diagnostic laboratories. This included feces that were 125 culture-positive or 46 culture-negative for Campylobacter, Salmonella, Shigella, STEC, or Y. enterocolitica. Using culture as a reference standard, the sensitivity for all organisms (excluding Yersinia) was >96% for all four assays and specificity was >90%, except for BD Max (87%).

The authors concluded that their study provided a third-party evaluation of four commercially available RT-PCR assays for bacterial gastroenteritis and demonstrated the assays to be mostly equivalent to each other and culture with a few caveats. Depending on the prevalence of certain stx sub-types, Yersinia species, and Campylobacter species in a laboratory's jurisdiction, without further improvement in culture-independent tests, culture methods remain critical for the detection of these pathogens. The study was published on January 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
University of Calgary
R-Biopharm
Fast Track Diagnostics
BD Canada
Hologic


Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
POC RT-PCR COVID-19 Testing Platform
Convergys POC RT-PCR COVID-19 Testing Platform
New
UV/Vis Spectrophotometer
BioDrop DUO+
New
High Throughput Electrolyte Analyzer
CBS-50

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more

Hematology

view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.